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Objectives: This study aimed to investigate the correlation between cardiovascular 
(CV) health and CV disease knowledge of Life’s Simple 7 (LS7) among 3 age groups in 
Hong Kong – young adults, middle aged, and the elderly. MethOds: Young adults 
and middle-aged adults were identified from the on-campus health check at the 
Chinese University of Hong Kong. Elderly subjects were recruited from the com-
munity outreach in 15 community elderly centers. The subjects’ demographics, 
lifestyle behavior and risk knowledge were obtained through a validated question-
naire. The body mass index, random capillary blood glucose, blood cholesterol and 
blood pressure were measured during the on-campus health check and community 
outreach sessions. LS7 score and risk knowledge score for each subject were calcu-
lated. Logistic regression was used to estimate the odd ration and 95% confidence 
intervals for the demographic characteristics on LS7 and knowledge. Results: A 
total of 996 subjects were included in this study (mean age: 56.3 ± 25.5 years old; 28% 
male). There were only 0.6% subjects had ideal CV health while 35.9% had 5 to 7 ideal 
CV health metrics. Subjects ≥ 65 years (OR 2.341, 95% CI 1.779-3.080, P < 0.0005) and 
subjects with tertiary education or above (OR 2.031, 95% CI 1.527-2.701, P < 0.0005) 
were more likely to obtain optimum LS7 (scoring ≥ 10 out of 14 in LS7 score). Subjects 
≤ 65 years (OR 1.695, 95% CI 1.297-2.215, P < 0.0005) and those with tertiary education 
or above (OR 1.859, 95% CI 1.412-2.448, P < 0.0005) were more likely to obtain full CV 
disease risk knowledge score. No association was found between having optimum 
LS7 and full CV knowledge. cOnclusiOns: Less than 1% of adults in this study 
population had ideal CV health as defined by AHA. Knowledge has no association 
but young age and tertiary education had positive association with CV health.
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Objectives: Genotype-guided therapy has been demonstrated to enhance the accu-
racy of warfarin dosing. However, factors that limit the predictive accuracy of this 
approach have not been evaluated in a heterogeneous population. This study identi-
fied patient characteristics and clinical factors that contributed to poor prediction of 
a warfarin therapeutic dose when using a genotyped-guided approach. MethOds: 
This was a prospective observational study of patients managed by the University of 
Illinois Hospital and Health Sciences System Pharmacogenetics Service who have 
attained a warfarin therapeutic dose. The primary outcome was a large dose devia-
tion (> 20%) between the genotype-guided predicted dose and the actual warfarin 
therapeutic dose. Variables examined included patient demographics, interacting 
medications, comorbidities, genotype information, baseline international normal-
ized ratio, and reason for anticoagulation. Multivariate logistic regression was used 
to estimate the odds ratio (OR) for a large dose deviation. Results: Of the 146 
consecutive patients enrolled, 23.3% were Hispanics, 54.1% were African American, 
and the mean age was 54.2±17.9 years. Fifty-three percent of the study cohort had a 
large dose deviation. After adjusting for potential confounders, being middle aged 
(41-65 vs. 18-40 years) and Hispanic (vs. Whites and Asians) had a 4.15-fold (95%CI 
1.24-13.95, p= 0.021) and 7.58-fold (95%CI 1.69-33.93, p= 0.008) increased odds for 
a large dose deviation, respectively. Patients who took warfarin for thrombosis 
prophylaxis versus treatment were 3.2-fold more likely to have a large dose devia-
tion (95%CI 1.14-8.99, p= 0.027). In addition, patients who required a high warfarin 
maintenance dose (> 7.5mg/day) versus average dose (3-7.5 mg/day) were at an 
elevated risk (adjusted OR 5.21, 95%CI 1.30-20.78, p= 0.019) of having a large dose 
deviation. cOnclusiOns: Our results highlight factors that might contribute to 
poor prediction of warfarin dosing using a genotype-guided approach and sug-
gest that methods to refine dose prediction are needed for under-studied patient 
populations, including Hispanics and patients receiving warfarin for thrombosis 
prophylaxis.
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Objectives: Elevated low density lipoprotein cholesterol (LDL-C) and low high 
density lipoprotein cholesterol (HDL-C) level is a characteristic of dyslipidemia. 
Increase in blood lipids levels has the potential to cause hepatic disorders such as 
non-alcoholic fatty liver disease and liver cirrhosis. The goal of this study was to 
examine the association between liver enzymes and lipid levels amongst adults 
in the United States. MethOds: The National Health and Nutrition Examination 
Survey (NHANES) data from 2005 to 2006 was used to examine the association 
between liver enzymes and lipid levels amongst adults in the United States. Data 
were analyzed for descriptive statistics and for differences using the t-test, Chi 
square test and ANOVA. A regression analysis was performed to identify relation-
ships between demographic characteristics, liver enzymes and lipid levels. A p value 
of < 0.05 was considered statistically significant. Results: A total of 2,201 adults 
(20 yrs. and above) were included in this study. Sample mean age was 48 ± 19 yrs. 
Thirty eight percent adults had LDL-C levels greater than 130mg/dL and 14% had 
HDL-C levels greater than 60mg/dL according to National Cholesterol Education 
Program - Adult Treatment Panel (NCEP-ATP III) guidelines. A significant relation-
ship was observed between HDL-C and alkaline phosphotase levels (ALP), LDL-C 
and asparatate aminotransferase (AST), triglycerides and AST levels (p< 0.05). Adults 
with LDL-C > 100mg/dL were associated with two times higher odds of abnormal 
AST levels (95%CI:1.5–2.8, p< 0.001), whereas, HDL-C levels < 60 mg/dL were associ-
ated with 2.9 times higher odds of abnormal AST levels (95%CI:2.2–3.7, p< 0.001). 
Regression analysis showed significant relationship between LDL-C, HDL-C, tri-
glycerides, ALT, AST, ALP and age (p< 0.05). cOnclusiOns: There was significant 
association between abnormal asparatate aminotransferase and low HDL-C levels, 
even though low HDL-C levels are desirable to reduce cardiovascular risks. There 
of hypertension in 2008 varied by country (US= 15.6%, UK= 23.4%, Australia= 18.2%, 
Canada= 15.3%, and Saudi Arabia= 31.2%). There were 138 antihypertensive medica-
tions and 61 combinations available in all five countries. The US had the highest 
number of antihypertensive medications (70.0%), followed by Canada (56.5%), UK 
(52.8%), Australia (51.44%) and Saudi Arabia (49.2%). There were 31 combinations 
of antihypertensive medications with the FDA listing 50.8% of those combinations, 
followed by the UK (40.9%), Saudi Arabia and Australia (both 37.7%), and Canada 
(34.4%).The therapeutic classes with the larger number of approvals were beta 
blockers (n= 14), angiotensin-converting enzyme inhibitors (n= 11) and thiazide 
diuretics (n= 11). The relationship between the number of antihypertensive drugs 
approved and hypertension prevalence appeared inverse, (Spearman correlation 
coefficient= -0.8), yet non-significant (P= 0.10), most likely due to lack of power 
(n= 5) and the ecological nature of this correlation. cOnclusiOns: Differences exist 
in the number of antihypertensive medications and therapeutic classes available 
in each country. The US had the highest access to antihypertensive medications 
among the countries included in the study. Further studies are needed to assess 
the utilization of antihypertensive medications and the potential relationship with 
hypertension prevalence.
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Objectives: Although the number of patients with PAH who were certified as 
patients of Specified Rare and Intractable Diseases is annually provided by the 
Ministry of Health, Labor and Welfare (MHLW) in Japan, the morbidity rate and 
treatment situation for PAH has not been clearly investigated yet. This study aimed 
to investigate morbidity rate of PAH using a Japanese healthcare database. The 
pharmaceutical intervention for PAH was also investigated among those with 
PAH. MethOds: The Japanese healthcare database which contains approximately 
2.1 million subjects covered by employment-based health insurance (MinaCare Co. 
Ltd) was used for this study. The patients with PAH who were newly diagnosed 
as Pulmonary Hypertension (PH) between September 1, 2011 and August 31, 2012 
and prescribed at least 1 anti-PAH drug was extracted. The patients with PH were 
identified by using International Classification of Diseases (ICD)-10 codes (I270, I271, 
I272, I278, I279 and P293) or by free formatdiagnosis name including “Pulmonary 
Hypertension”. Results: Of approximately 1.1 million person-years of observation, 
34 were identified as newly diagnosed PAH patients. Therefore, the crude rate of PAH 
morbidity was 30.4 per 1,000,000 person-years. The commonly used medication as 
the first treatment among these 34 patients were Beraprost(70.6%), Sildenafil(20.6%), 
Tadalafil(5.9%) and Bosentan(5.9%). cOnclusiOns: This is the first report to show 
the morbidity rate of PAH in Japan. This study revealed that Beraprost was the most 
commonly used first PAH treatment agent in Japan in the real-world data setting, 
although Sildenafil and Bosentan are recommended to be used as the 1st line treat-
ment in the Guideline for “Treatment of Pulmonary Hypertension” (JCS2012). In 
order to improve the quality of PAH treatment and the patients’ outcome, it is highly 
important to increase awareness of the recommended treatment and fill the gap 
between the guideline and actual clinical use of these drugs.
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Objectives: Inflammation contributes to the pathogenesis of both psoriasis 
and arrhythmia, and psoriasis has been shown to be associated with substantial 
cardiovascular morbidity and mortality. On the other hand, however, only a few 
small studies have investigated the risk of arrhythmia in psoriasis. The aim of this 
study was to determine whether patients with psoriasis have an increased risk of 
arrhythmia. MethOds: A retrospective, population-based matched cohort study 
of patients with psoriasis was conducted from January 1, 2003, to December 31, 
2011. New-onset psoriasis patients (n= 40637) and psoriasis-free matched controls 
(n= 162548) were followed, with a mean follow-up of 6.41 years. Diagnoses and 
prescriptions of the patients were obtained from the National Health Insurance 
Research Database (NHIRD), Taiwan. Patients with psoriasis were classified as severe 
if they received a systemic antipsoriatic therapy and/or phototherapy or otherwise, 
mild. Risk of arrhythmia was analyzed by using a multivariable Cox proportional 
hazards regression model. Results: There were 3910 arrhythmia (9.62%) within the 
psoriasis patients and 11612 (7.14%) arrhythmia within the comparison subjects, 
and the incidences per 100000 person-years were 1541.37 and 1106.09, respectively. 
After adjusted for comorbidities and medications, the incidence risk of arrhythmia 
was increased in all groups of psoriasis patients compared to the controls. The 
adjusted hazard ratios (95% confidence intervals) for arrhythmia were 1.30 (1.25 to 
1.35), 1.31 (1.25 to 1.36), 1.21 (1.09 to 1.34), 1.37(1.16 to 1.62) and 1.29 (1.24-1.34) in the 
overall, mild, severe psoriasis, psoriasis patient with psoriatic arthritis (PsA), and 
psoriasis patients without PsA (PsC), respectively. cOnclusiOns: Patients with 
psoriasis have a higher risk of developing arrhythmia, independent of traditional 
cardiovascular risk factors. Moreover, the risk of arrhythmia in PsA was higher than 
PsC. Increased awareness of the arrhythmia risk in the cardiovascular assessment 
in psoriasis patients is recommended.
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